Therefore, BAG-1 codon 324 gene polymorphism serves as a biomarker for predicting the sensitivity of chemotherapy, and may provide a theoretical basis for individual treatment of patients with advanced NSCLC. This evidence concerns the gene BAG1 and non-small cell lung carcinoma.